Mind Technology, Inc. shares rise 3.54% intraday after Neurolief's strategic investment and FDA approval anticipation for Proliv™Rx.

Mind Technology, Inc. rose 3.54% intraday, with the company's strategic investment in Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, marking a significant milestone as Neurolief awaits FDA approval and prepares for the commercial launch of its Proliv™Rx system designed for the treatment of Major Depressive Disorder (MDD). This investment reflects an exciting strategic alignment between the two companies, both dedicated to expanding access to innovative, clinically validated, and non-invasive mental health treatments.